Author Archives: Steve Walker

Healthcare stocks display their resilience after bear market struck in December; well, most do.

The News: We’re hardly in a recession, and most forms of healthcare spending remain incredibly robust, regardless of what the overall economy does and what the White House says about… Read more »

Healthcare IPO dreamers not ready to throw in the towel despite recent market slump. Will 2019 stack up to 2018?

It’s now Daylight Saving Time and the question on the heretofore gloomy minds of a lot of us healthcare stock editorialists is: Will it be boom or kaboom for IPOs… Read more »

Voyager Therapeutics signs another neurodegenerative disease deal with AbbVie that screams “Buy this small cap now.”

The News: Voyager Therapeutics Inc. (Cambridge MA) struck a deal with AbbVie Inc. (North Chicago) to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s… Read more »

It’s time to reclassify schizophrenia as a neurologic disorder.

The News: A mental health advocacy group has spearheaded a new initiative to reclassify schizophrenia as a neurologic, rather than a psychiatric, disease. The action is designed to reduce stigma and ultimately… Read more »

Healthcare stocks keep rockin as February begins with searing action. Will it last, or flame out?

Winners far outpaced losers last week as the broader market continued to worry about trade talks with China and the prospect of another government shutdown over the Trump wall. Check… Read more »

Healthcare IPOs keep rolling along, and not just in the US. Will March come in like a lion, or a lamb?

The News: While markets take a breather during this holiday shortened week, any big IPO news in the US will likely come in the form of new filings. A company… Read more »